Arbutus Biopharma
ABUS
111 hedge funds and large institutions have $152M invested in Arbutus Biopharma in 2023 Q2 according to their latest regulatory filings, with 12 funds opening new positions, 38 increasing their positions, 30 reducing their positions, and 22 closing their positions.
107% more call options, than puts
Call options by funds: $2.34M | Put options by funds: $1.13M
27% more repeat investments, than reductions
Existing positions increased: 38 | Existing positions reduced: 30
1.43% more ownership
Funds ownership: 38.44% → 39.87% (+1.4%)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
9% less funds holding
Funds holding: 122 → 111 (-11)
19% less capital invested
Capital invested by funds: $189M → $152M (-$36.9M)
45% less first-time investments, than exits
New positions opened: 12 | Existing positions closed: 22
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$5.4M |
| 2 |
BlackRock
New York
|
+$3.92M |
| 3 |
TSC
Two Seas Capital
Rye,
New York
|
+$2.12M |
| 4 |
WCM
Whitefort Capital Management
New York
|
+$1.55M |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$807K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCMNY
Rubric Capital Management (New York)
New York
|
-$2.08M |
| 2 |
FCM
FourWorld Capital Management
New York
|
-$1.71M |
| 3 |
Wellington Management Group
Boston,
Massachusetts
|
-$848K |
| 4 |
Two Sigma Investments
New York
|
-$803K |
| 5 |
JP Morgan Chase
New York
|
-$492K |
ABUS Hedge Fund Activity: Q2 2023 in Review
111 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in Arbutus Biopharma (ABUS) for Q2 2023, worth a combined $152M — down 19% from $189M a quarter earlier.
Sellers outnumbered buyers: 22 funds closed out of ABUS and 12 opened new positions — a net loss of 10 holders — while 30 trimmed existing stakes and 38 added.
The largest buyer was Citadel Advisors, adding an estimated $5.4M. The largest seller was Rubric Capital Management (New York), cutting an estimated $2.08M.
- 111 institutional investors held Arbutus Biopharma (ABUS) as of Q2 2023, down from 122 in Q1 2023.
- Funds reported $152M of Arbutus Biopharma stock for Q2 2023, down 19% quarter-over-quarter.
- 12 funds opened new Arbutus Biopharma positions in Q2 2023 and 22 closed out, a net change of -10 holders.
- The largest Arbutus Biopharma buyer in Q2 2023 was Citadel Advisors, an estimated $5.4M added.
- The largest Arbutus Biopharma seller in Q2 2023 was Rubric Capital Management (New York), an estimated $2.08M sold.
Based on aggregated 13F filings for Q2 2023.